MX2009004140A - Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3. - Google Patents

Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.

Info

Publication number
MX2009004140A
MX2009004140A MX2009004140A MX2009004140A MX2009004140A MX 2009004140 A MX2009004140 A MX 2009004140A MX 2009004140 A MX2009004140 A MX 2009004140A MX 2009004140 A MX2009004140 A MX 2009004140A MX 2009004140 A MX2009004140 A MX 2009004140A
Authority
MX
Mexico
Prior art keywords
glycogen synthase
synthase kinase
inhibitors
heterocyclic compounds
compounds
Prior art date
Application number
MX2009004140A
Other languages
English (en)
Inventor
Kent D Stewart
Sean Colm Turner
Margaretha Henrica Maria Bakker
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MX2009004140A publication Critical patent/MX2009004140A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención se refiere a un compuesto heterocíclico de fórmula general (I) y su uso y su preparación, métodos para preparar los compuestos, composiciones que contienen al menos uno de dichos compuestos, y métodos de tratamiento donde se usa al menos un compuesto. En particular, los compuestos de fórmula general (I) son útiles para inhibir la glucógeno sintasa quinasa 3 (GSK-3). (ver fórmula (I)).
MX2009004140A 2006-10-21 2007-10-19 Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3. MX2009004140A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06022094 2006-10-21
US93683707P 2007-06-22 2007-06-22
PCT/EP2007/061231 WO2008046919A2 (en) 2006-10-21 2007-10-19 Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors

Publications (1)

Publication Number Publication Date
MX2009004140A true MX2009004140A (es) 2009-07-10

Family

ID=41232240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004140A MX2009004140A (es) 2006-10-21 2007-10-19 Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.

Country Status (16)

Country Link
US (2) US8642598B2 (es)
EP (2) EP2535336A1 (es)
JP (1) JP5406030B2 (es)
KR (1) KR20090071662A (es)
CN (1) CN101573352A (es)
AU (1) AU2007312165A1 (es)
BR (1) BRPI0717618A2 (es)
CA (1) CA2666590C (es)
CO (1) CO6160330A2 (es)
CR (1) CR10722A (es)
EC (1) ECSP099351A (es)
ES (1) ES2445791T3 (es)
IL (1) IL198007A0 (es)
MX (1) MX2009004140A (es)
RU (1) RU2009119181A (es)
WO (1) WO2008046919A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090071662A (ko) 2006-10-21 2009-07-01 애보트 게엠베하 운트 콤파니 카게 헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
TWI587860B (zh) * 2016-05-06 2017-06-21 國立臺灣師範大學 喹啉衍生化合物用於製備Ｔａｕ蛋白病變類疾病之醫藥組成物上之用途
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11780840B2 (en) 2020-07-02 2023-10-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
CN1518543A (zh) * 2000-08-31 2004-08-04 �Ʒ� 吡唑衍生物和它们作为蛋白激酶抑制剂的用途
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN1317030C (zh) * 2001-04-30 2007-05-23 赞塔里斯有限公司 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病
DE10123586A1 (de) * 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2002334217B2 (en) 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
AU2002364536B2 (en) * 2001-12-07 2008-10-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
ES2289171T3 (es) 2001-12-21 2008-02-01 Astrazeneca Ab Uso de derivados de oxindol en el tratamiento de trastornos relacionados con la demencia, de la enfermedad de alzheimer y afecciones asociadas con glucogeno sintasa quinasa-3.
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1613629A1 (en) * 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
AU2004267094A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors
WO2005061516A1 (en) 2003-12-04 2005-07-07 Smithkline Beecham Corporation Novel chemical compounds
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
WO2005120509A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
WO2006003440A1 (en) 2004-07-05 2006-01-12 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP5345388B2 (ja) 2005-06-30 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 環式アニリノ−ピリジノトリアジン
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
AR055669A1 (es) 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
US20090170847A1 (en) 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
EP1981500A4 (en) 2006-02-02 2010-08-25 Astrazeneca Ab PHARMACEUTICAL USE OF 2-HYDROXY-3- [5- (MORPHOLIN-4-YLMETHYL) PYRIDINE-2-YL] -1H-INDOL-5-CARBONITRIL AS FREE BASE OR SALT
WO2007120102A1 (en) 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
EP1849785A1 (en) 2006-04-28 2007-10-31 Neuropharma, S.A. N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
KR20090071662A (ko) 2006-10-21 2009-07-01 애보트 게엠베하 운트 콤파니 카게 헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
EP2099787B1 (en) 2006-12-19 2010-07-21 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as inhibitors of protein kinases
WO2008130312A1 (en) 2007-04-18 2008-10-30 Astrazeneca Ab A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701
EP1992624A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
JP5756011B2 (ja) 2008-04-24 2015-07-29 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Also Published As

Publication number Publication date
ECSP099351A (es) 2009-06-30
AU2007312165A1 (en) 2008-04-24
BRPI0717618A2 (pt) 2013-10-22
US9856234B2 (en) 2018-01-02
KR20090071662A (ko) 2009-07-01
RU2009119181A (ru) 2010-11-27
CN101573352A (zh) 2009-11-04
IL198007A0 (en) 2009-12-24
JP2010507575A (ja) 2010-03-11
JP5406030B2 (ja) 2014-02-05
CO6160330A2 (es) 2010-05-20
EP2091943A2 (en) 2009-08-26
US8642598B2 (en) 2014-02-04
EP2091943B1 (en) 2013-11-20
ES2445791T3 (es) 2014-03-05
EP2535336A1 (en) 2012-12-19
US20140148458A1 (en) 2014-05-29
CA2666590A1 (en) 2008-04-24
CR10722A (es) 2009-08-24
CA2666590C (en) 2015-10-06
WO2008046919A2 (en) 2008-04-24
US20100324042A1 (en) 2010-12-23
WO2008046919A3 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
MY148634A (en) Pyridazinone derivatives
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2009013213A (es) Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
MX2012013197A (es) Inhibidores de indazol de cinasa.
WO2010002655A3 (en) Pyrimidine derivatives as kinase inhibitors
MX2007008555A (es) Amino-imidazolonas para la inhibicion de (-secretasa.
MX2011013325A (es) 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MX2009013077A (es) Derivados dde benzoxazolona.
WO2009158431A3 (en) Pyrimidine derivatives as kinase inhibitors
WO2009156041A3 (de) Thiazolyl-piperidinderivate
MY152042A (en) 3,4- substituted piperidine derivatives as renin inhibitors
IL207639A (en) PyrrollopyrimidineCarboxylate compounds, preparations containing them and their uses
GEP20125547B (en) (aza) indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2011012631A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2011007165A (es) Derivados de piridazinona.
WO2008087654A3 (en) PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
WO2010066028A8 (en) 3,4 - substituted piperidine derivatives as renin inhibitors
TN2012000034A1 (en) Methylpyrrolopyrimidinecarboxamides
TW200800993A (en) Organic compounds

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration
GB Transfer or rights
PD Change of proprietorship

Owner name: ABBVIE INC.